We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
- Authors
Ramalingam, Suresh S; Kummar, Shivaani; Sarantopoulos, John; Shibata, Stephen; LoRusso, Patricia; Yerk, Mara; Holleran, Julianne; Lin, Yan; Beumer, Jan H; Harvey, R Donald; Ivy, S Percy; Belani, Chandra P; Egorin, Merrill J
- Abstract
Vorinostat is the first US Food and Drug Administration-approved histone deacetylase inhibitor and is indicated for the treatment of refractory cutaneous T-cell lymphoma. We conducted a phase I study to determine the maximum-tolerated dose and pharmacokinetics of vorinostat in patients with hepatic dysfunction.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Vol 28, Issue 29, p4507
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2010.30.2307